Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study

被引：1
|
作者：
Naito, Yoichi [1 ]
Doi, Toshihiko [1 ]
Takahashi, Tsuyoshi [2 ]
Kudo, Toshihiro [2 ]
Boku, Narikazu [3 ]
Honma, Yoshitaka [3 ]
Komatsu, Yoshito [4 ]
Nakatsumi, Hiroshi [4 ]
Matsumoto, Koji [5 ]
Onoe, Takuma [5 ]
Oki, Eiji [6 ]
Tsuda, Yasuo [6 ]
Nakamoto, Masako [1 ]
Fukutani, Miki [1 ]
Nomura, Shogo [1 ]
Sato, Akihiro [1 ]
Nishida, Toshirou [3 ]
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Osaka Univ, Grad Sch Med, Suita, Osaka, Japan
[3] Natl Canc Ctr, Tokyo, Japan
[4] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan
[5] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[6] Kyushu Univ, Fukuoka, Fukuoka, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz339.023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2 - 5 - 3
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [1] Regorafenib as second-line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST)
    Takahashi, Tsuyoshi
    Nishida, Toshirou
    Kudo, Toshihiro
    Boku, Narikazu
    Honma, Yoshitaka
    Komatsu, Yoshito
    Nakatsumi, Hiroshi
    Matsumoto, Koji
    Onoe, Takuma
    Oki, Eiji
    Nakamoto, Masako
    Fukutani, Miki
    Nomura, Shogo
    Sato, Akihiro
    Naito, Yoichi
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [2] A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).
    Trent, J. C.
    Wathen, K.
    von Mehren, M.
    Samuels, B. L.
    Staddon, A. P.
    Choy, E.
    Butrynski, J. E.
    Chugh, R.
    Chow, W. A.
    Rushing, D. A.
    Forscher, C. A.
    Baker, L. H.
    Schuetze, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
    George, S.
    von Mehren, M.
    Heinrich, M. C.
    Wang, Q.
    Corless, C. L.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    Choy, E.
    Tap, W. D.
    Manola, J.
    Yap, J. T.
    Van den Abbeele, A. D.
    Solomon, S.
    Fletcher, J. A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update
    Blay, J. Y.
    Casali, P. G.
    Reichardt, P.
    von Mehren, M.
    Debiec-Rychter, M.
    Bailey, S.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST).
    Yip, Desmond
    Zalcberg, John Raymond
    Blay, Jean-Yves
    Eriksson, Mikael
    Espinoza, David
    Price, Timothy Jay
    Marreaud, Sandrine
    Italiano, Antoine
    Steeghs, Neeltje
    Boye, Kjetil
    Underhill, Craig
    Naher, Sayeda
    Oostendorp, Martinus
    Gebski, Val
    Simes, John
    Gelderblom, Hans
    Joensuu, Heikki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
    Sako, Hiroyuki
    Fukuda, Kazumasa
    Saikawa, Yoshiro
    Nakamura, Rieko
    Takahashi, Tsunehiro
    Wada, Norihito
    Kawakubo, Hirohumi
    Takeuchi, Hiroya
    Ohmori, Tai
    Kitagawa, Yuko
    PLOS ONE, 2014, 9 (09):
  • [7] A phase I study of nilotinib alone and in combination with imatinib in patients (PTS) with imatinib-resistant gastrointestinal stromal tumors (GIST) -: Study update
    Reichardt, Peter
    Casali, Paolo G.
    Blay, Jean-Yves
    von Mehren, Margaret
    Schoffski, Patrick
    Tanaka, Chiaki
    Jalaluddin, Muhammad
    Veronese, Maria Luisa
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [8] A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)
    Dumez, H.
    Reichard, P.
    Blay, J. Y.
    Schoeffski, P.
    Morgan, J. A.
    Ray-Coquard, I. L.
    Hollaender, N.
    Jappe, A.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).
    Reichardt, P.
    Casali, P. G.
    Blay, J.
    Von Mehren, M.
    Schoffski, P.
    Hosseinzadeh, S.
    Tanaka, C.
    Gsponer, T.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 531S - 531S
  • [10] Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
    Huang, Wen-Kuan
    Gao, Jiwei
    Chen, Ziqing
    Shi, Hao
    Yuan, Juan
    Cui, Huanhuan L.
    Yeh, Chun-Nan
    Branstrom, Robert
    Larsson, Catharina
    Li, Shuijie
    Lui, Weng-Onn
    CELLS, 2020, 9 (06)
12345